amifostine anhydrous has been researched along with Hypocalcemia in 5 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Hypocalcemia: Reduction of the blood calcium below normal. Manifestations include hyperactive deep tendon reflexes, Chvostek's sign, muscle and abdominal cramps, and carpopedal spasm. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty women with cervical cancer were enrolled in a clinical trial to determine the maximal safe dose of WR2721 plus radiation therapy and cisplatin on a novel daily x 5 schedule." | 2.67 | Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy. The New York Gynecologic Oncology Group. ( Beitler, JJ; Bruckner, H; Goldberg, G; Haynes, H; Hochster, H; Holland, JF; Mandeli, J; Runowicz, C; Smith, H; Wadler, S, 1993) |
| "Transient hypotension was the most common side effect occurring in association with amifostine." | 1.31 | Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study. ( Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E, 2001) |
| "Sixteen patients with advanced cancers had serial measurements of serum calcium and other studies of blood chemistry before and after taking the compound." | 1.27 | Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent). ( Agus, ZS; Attie, M; Carmichael, K; Glick, J; Glover, D; Goldfarb, S; Kligerman, MM; Riley, L; Slatopolsky, E; Spar, B, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gallegos-Castorena, S | 1 |
| Martínez-Avalos, A | 1 |
| Mohar-Betancourt, A | 1 |
| Guerrero-Avendaño, G | 1 |
| Zapata-Tarrés, M | 1 |
| Medina-Sansón, A | 1 |
| Ozkaynak, MF | 1 |
| Sahdev, I | 1 |
| Gross, TG | 1 |
| Levine, JE | 1 |
| Cheerva, AC | 1 |
| Richards, MK | 1 |
| Rozans, MK | 1 |
| Shaw, PJ | 1 |
| Kadota, RP | 1 |
| Glover, D | 1 |
| Riley, L | 1 |
| Carmichael, K | 1 |
| Spar, B | 1 |
| Glick, J | 1 |
| Kligerman, MM | 1 |
| Agus, ZS | 1 |
| Slatopolsky, E | 1 |
| Attie, M | 1 |
| Goldfarb, S | 1 |
| Wadler, S | 1 |
| Haynes, H | 1 |
| Beitler, JJ | 1 |
| Goldberg, G | 1 |
| Holland, JF | 1 |
| Hochster, H | 1 |
| Bruckner, H | 1 |
| Mandeli, J | 1 |
| Smith, H | 1 |
| Runowicz, C | 1 |
| Genvresse, I | 1 |
| Lange, C | 1 |
| Schanz, J | 1 |
| Schweigert, M | 1 |
| Harder, H | 1 |
| Possinger, K | 1 |
| Späth-Schwalbe, E | 1 |
3 trials available for amifostine anhydrous and Hypocalcemia
| Article | Year |
|---|---|
Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.
Topics: Adolescent; Amifostine; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; | 2007 |
A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplan | 2008 |
Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy. The New York Gynecologic Oncology Group.
Topics: Adult; Aged; Amifostine; Calcitriol; Calcium; Calcium, Dietary; Cisplatin; Combined Modality Therapy | 1993 |
2 other studies available for amifostine anhydrous and Hypocalcemia
| Article | Year |
|---|---|
Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent).
Topics: Amifostine; Animals; Antineoplastic Agents; Calcium; Cattle; Drug Evaluation; Humans; Hydrogen-Ion C | 1983 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Com | 2001 |